The approval has been confirmed for the UK, Belgium, Finland, Ireland, Luxemburg, Netherlands and Sweden.
Octapharma’s manufacturing process for OctaplasLG, which is a solvent/detergent treated, prion-reduced, plasma product is incorporated with prion capture resin, PrioClear by ProMetic.
ProMetic has secured a purchase order and binding forecast from Octapharma for around $3m of PrioClear resin to be manufactured between December 2011 and June 2012.
ProMetic Life Sciences CEO Pierre Laurin said these countries are major markets for their growth along with Octapharma.
"We expect other key markets to adopt and follow the industry’s migration towards safer plasma derived products and we are pleased with Octpharma’s plan to advance OctaplassLG in North America," Laurin added.